Skip to main content

STERIS plc (Ireland) (STE) Stock Analysis

Recovery setup

HoldModerate Confidence

Healthcare · Medical Devices

Hold if already holding. Not a fresh buy at $214.42, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.2%.

STERIS (Ireland) is a global provider of infection prevention and sterilization products/services for healthcare, contract sterilization (AST), and life sciences customers. Three segments earn revenue from consumables, equipment maintenance, and outsourced reprocessing services... Read more

$214.42+4.2% A.UpsideScore 5.8/10#11 of 40 Medical Devices
QualityF-score9 / 9FCF yield2.81%
IncomeYield1.18%(5y avg 0.90%)Payout31.02%sustainable
Stop $200.32Target $223.47(analyst − 13%)A.R:R 0.5:1
Analyst target$256.86+19.8%7 analysts
$223.47our TP
$214.42price
$256.86mean
$280

Hold if already holding. Not a fresh buy at $214.42, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.2%. Chart setup: Death cross but MACD improving, RSI 52. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.

Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Val5.4Qual6.4Grw7.2Mom5.8Sent6.3Ins5.0Peer3.7Tech5.0Risk6.35.8OVERALL

Recent Developments — STERIS plc (Ireland)

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong growth profile
Risks
Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials)
Thin upside margin: 4.2%
Below 200-day MA

Key Metrics

P/E (TTM)26.8
P/E (Fwd)17.6
Mkt Cap$20.9B
EV/EBITDA16.3
Profit Mgn13.2%
ROE11.4%
Rev Growth7.3%
Beta0.95
Dividend1.18%
Rating analysts15

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C3.36bearish
IV35%normal

Concentration Risks(10-K Item 1A)

  • HIGHSupplierethylene oxide and cobalt-60 (single-source AST materials)
    10-K Item 1: 'We have long-term supply contracts for certain materials...such as ethylene oxide ("EO") and radioisotope cobalt-60 ("cobalt-60"), which are necessary to our AST operations.'

Material Events(8-K, last 90d)

  • 2026-05-07Item 5.02LOW
    Richard C. Breeden not standing for re-election at 2026 AGM (no disagreement cited). Pierre Boulud (CEO of bioMérieux) appointed as new director effective May 5, 2026, joining Audit Committee and R&D Committee.
    SEC filing →
  • 2026-04-06Item 5.02LOW
    Amendment to Transition Agreement with former CFO Michael J. Tokich extends part-time senior financial advisor role through March 31, 2027 at reduced $60,000 annual salary. Routine transition arrangement.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
4.0
Value Rank
4.1
Quality Rank
6.6
GatesA.R:R 0.5 < 1.5@spotDeath cross (50MA < 200MA)Momentum 5.8>=5.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
52 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $195.14Resistance $227.34

Price Targets

$200
$223
A.Upside+4.2%
A.R:R0.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Reward/Risk 0.5:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-05 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is STE stock a buy right now?

Hold if already holding. Not a fresh buy at $214.42, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.2%. Chart setup: Death cross but MACD improving, RSI 52. Maintain position. Not compelling to add more. Target $223.47 (+4.2%), stop $200.32 (−7.0%), A.R:R 0.5:1. Score 5.8/10, moderate confidence.

What is the STE stock price target?

Take-profit target: $223.47 (+4.2% upside). Target $223.47 (+4.2%), stop $200.32 (−7.0%), A.R:R 0.5:1. Stop-loss: $200.32.

What are the risks of investing in STE?

Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.2%; Below 200-day MA.

Is STE overvalued or undervalued?

STERIS plc (Ireland) trades at a P/E of 26.8 (forward 17.6). TrendMatrix value score: 5.4/10. Verdict: Hold.

What do analysts say about STE?

15 analysts cover STE with a consensus score of 3.9/5. Average price target: $257.

What does STERIS plc (Ireland) do?STERIS (Ireland) is a global provider of infection prevention and sterilization products/services for healthcare,...

STERIS (Ireland) is a global provider of infection prevention and sterilization products/services for healthcare, contract sterilization (AST), and life sciences customers. Three segments earn revenue from consumables, equipment maintenance, and outsourced reprocessing services with no single customer exceeding 10% of any segment's revenues.

Related stocks: GMED (Globus Medical, Inc.) · PODD (Insulet Corporation) · BSX (Boston Scientific Corporation) · DXCM (DexCom, Inc.) · LIVN (LivaNova PLC)